Skip to main content
. Author manuscript; available in PMC: 2024 Sep 6.
Published in final edited form as: Radiother Oncol. 2023 Sep 1;188:109892. doi: 10.1016/j.radonc.2023.109892

Figure 2. Predictors of improved MCC-specific and recurrence-free survival.

Figure 2.

(a) MCCS for HN vs. NHN patients, (b) MCCS for patients with T1 vs. T2 or greater primary tumors, (c) MCSS for patients without vs. with immunocompromise, (d) RFS for HN vs. NHN patients, (e) RFS for patients with T1 vs. T2 or greater primary tumors, (f) RFS for patients without vs. with immunocompromise.